1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Amylin gets full value from $7bn BMS/AZ acquisition

 
• By John Hodgson

Amylin appears to have realized full value for its Byetta/Bydureon franchise in diabetes through an acquisition by Bristol-Myers Squibb worth $31 per share, that will cost the pharma major some $7 billion, including the $1.7 billion in debt and obligations that Amylin holds. But what re-started the acquisition by BMS was the intervention by AstraZeneca to pay some $3.4 billion for certain rights to Amylin's portfolio and pipeline.

Amylin appears to have realized full value for its Byetta/Bydureon franchise in diabetes through an acquisition by Bristol-Myers Squibb worth $31 per share, that will cost the pharma major some $7 billion, including the $1.7 billion in debt and obligations that Amylin holds. But what re-started the acquisition by BMS was the intervention by AstraZeneca to pay some $3.4 billion for certain rights to Amylin's portfolio and pipeline.

The perfect storm for Amylin began when the development and commercialisation agreement between Amylin and Eli Lilly broke down in...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Alimentary/Metabolic

Metabolic Disease-Focused Poxel Teeters On The Edge

 
• By Andrew McConaghie

The Lyon, France-based company has filed for insolvency and is running out of time to find new funding for its metabolic disease pipeline.

Novo Selects Internal CEO To Recharge Growth

 
• By Jessica Merrill

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By Aakash Babu

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.

More from Therapeutic Category

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.